I am really proud to be Executive Chairman of Volition and am delighted with the progress the Company has made since its inception in 2011.

Dill Faulkes
Executive Chairman

A few words from our Executive Chairman

Our mission is simple: to save lives by revolutionizing the way disease, and especially cancer, is diagnosed. To this end, Volition is developing simple, easy to use blood-based tests to diagnose a range of cancers and other diseases.

Cancer is the second leading cause of death and is responsible for 1-in-6 deaths worldwide each year. It’s a disease that touches and affects so many of our lives. It is widely accepted that the best way of tackling cancer is for patients to receive an early diagnosis, as this improves their chances of surviving cancer.

I am delighted with the progress we have made in 2018 in the development of new tests using our technology platform of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid. I am also excited by the data that we expect to report throughout 2019 and beyond across such a broad range of cancers including: lung, colorectal, prostate, pancreatic, ovarian, and head and neck, as well as other diseases such as endometriosis.

Our research and development program during 2018 included some interesting proof of concept work in the veterinary field, including dogs and horses.

We believe that there is a high unmet clinical need for veterinary diagnostics and given the generally quicker USDA regulatory pathway to approval for veterinary products as compared to FDA approval for human products, Volition intends to develop products for this market as soon as possible which could provide early revenue for the company.

As our research develops, we are continuously growing our intellectual property portfolio which provides broad coverage (including animal use) that we believe will help protect our long-term competitive advantage.

Finally, I would like to thank the many collaborators we work with around the world and the Principal Investigators of our many clinical trials. I’d also like to acknowledge the contribution and continued support from the members of our Scientific Advisory Board and the continued financial support of the Walloon Region of Belgium. I look forward to announcing the results of key studies in this coming year.

Dill Faulkes
I am incredibly proud of the team we have assembled; individuals who come to work every day to create a brighter future, one where hope and cancer can come together in the same sentence.

I am absolutely delighted with the progress we have made on so many fronts in 2018, particularly with the work on the basics of our Nu.Q™ platform.

I am very happy to report the initial data from this work, and we expect to be able to report a large volume of data throughout 2019 and beyond with our newly optimized assays and matrices.

We have a strong financial position which we believe, given the cost effectiveness of our research and development program, provides a great runway to achieve our many milestones in 2019 and beyond.

I am delighted that our worldwide portfolio of granted patents that protect various aspects of Volition’s Nu.Q technology continues to grow. This is a key differentiator versus many other technologies either under development or available on the market, where the patent position may be poor and/or narrow.

From a research and development point of view, 2018 was a very busy year; however, it was fairly quiet in terms of press announcements, as we very much focused on platform development. Our team is delighted with the significant progress that has been made in 2018. I would like to thank our research and development team, for their tireless and tenacious efforts throughout the year. The vast majority of this work was focused on advancing the development of our clinical assays to the analytical validity needed for large clinical grade trials, and for products, as well as extending the use of our Nu.Q assays on a range of platforms.

This development work will be key to our future success and our initial assays have now completed this extremely vigorous process. This work has gone very well with our growing team at our large lab in Belgium. However, it is fair to say the development work on the robustness of our assays has proven to be a massive and time-consuming undertaking. Given that we are the first group to have worked in the field of Nucleosomics, much work had to be started from scratch.

I am delighted this report includes the initial results in three separate small cohorts with the first completed Nu.Q assay and one Nu.Q assay. In a lung cancer cohort (76 subjects), a single Nu.Q assay detected lung cancer, including stage I lung cancer. In this initial cohort, we achieved our best ever single-assay detection result with an AUC of 85% (lung cancer vs healthy), the performance of which was further improved when used in combination with a two-assay panel. In a second confirmatory lung cancer cohort (152 subjects) the same Nu.Q assay also detected lung cancer with an AUC of 79%.

This initial proof of concept data gave us confidence to move onto larger lung cancer studies and I’m delighted to have extended our collaboration with the National Taiwan University to embark upon a 1,200 subject lung cancer study in the second quarter of 2019.
Our new lab has enabled expansion of research and development programs from Nu.Q diagnostic tests to now include Nu.Q Vet and Nu.Q Capture.

In the fourth quarter of 2018, it was exciting to learn that not only could our Nu.Q technology help save lives and improve the quality of life for man-kind, but we are hopeful our technology will also be effective in helping diagnose a range of diseases in animals.

Following the completion of several small-scale studies in dogs, our subsidiary Volition America Inc. is now conducting a study of our Nu.Q Vet assays in cancer and other diseases in cooperation with Texas A&M University’s College of Veterinary Medicine, a leading U.S. veterinary institution. The U.S. is currently the largest veterinary market in the world and has a clearly defined regulatory pathway via the USDA, requiring fewer and smaller clinical studies than the FDA process for human diagnostics. This generally allows a much faster route to revenue for veterinary products as compared to human products, given trials need to be in the hundreds, not thousands of subject-samples.

From a commercial point of view, we are extremely excited about the opportunity to offer Nu.Q Vet tests to animal owners and veterinarians. There are currently no accurate, simple, affordable cancer screening or diagnostic tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life. We believe that this is a multi-billion-dollar opportunity and we aim to have the first Nu.Q Vet product on the market in 2020.

Our research and development team has grown significantly since we moved into our larger, purpose-built laboratory in Belgium in 2017. This has enabled expansion of our research and development programs from our Nu.Q diagnostic tests to now include not only Nu.Q Vet as described above, but also Nu.Q Capture.

The Nu.Q Capture project, leverages the work we have been doing to investigate the use of Nucleosomics to purify or enrich tumor associated nucleosomes. I am delighted to be able to announce that with Nu.Q Capture we have been able to deplete/enrich nucleosomes by 70-90% using magnetic beads in serum and plasma. The next step is to determine the level of discrimination of tumor associated nucleosomes using mass spectrometry and/or sequencing.

This potential breakthrough product aims to enrich tumor associated DNA which in turn will help address the main technology barrier to DNA cancer diagnostics.

Nu.Q Capture is platform agnostic with the ultimate aim of providing complete nucleosome analysis and origin of cancer. This is still very much a work in progress, but we have made significant progress this past year, and our team is very excited about this potential addition to our platform.

And so, to future milestones. As many of you know, we have concentrated our research efforts to date on colorectal cancer – which is the most preventable and yet currently least prevented form of cancer and we very much look forward to completing our large-scale clinical studies throughout 2019/2020.

In addition to our colorectal cancer studies, we are hopeful that our recent proof of concept results in lung cancer will be repeated in much larger cohorts, and with additional assays currently in development. Lung cancer remains the deadliest of all the cancers and we believe that there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test and/or for a test which can improve the specificity of the Low-Dose CT scan currently used in many markets.

We aim with our solid cash position, to report throughout 2019 and beyond Nu.Q’s ability to detect a range of cancers including lung, colorectal, prostate, pancreatic, ovarian, head and neck in addition to our 27-cancer study, and other conditions such as endometriosis as well as data from both the Nu.Q Vet and Nu.Q Capture programs.

We are grateful through our on-going trial program to be working with renowned collaborators around the world, all of whom have outstanding reputations and share our aim in improving early diagnosis of cancer.

We believe that Nu.Q will provide a low-cost routine blood test allowing doctors to check off an extra box along with other routine blood tests, such as cholesterol and PSA, during a single visit, and that this is currently the only credible way of taking compliance with screening above 80%.

We are extremely proud of the accomplishments we have achieved thus far and look forward to what the future holds for Volition, I, along with the rest of the Board, and indeed the whole company, look forward to sharing the results of key studies over the coming year with our optimized platform.

We work hard every day to create a brighter future, one where hope and cancer can come together in the same sentence.
We closed 2018 with $13.4 million cash and cash equivalents compared to $10.1 million as of the end of 2017.

In the first quarter of 2018, we raised $8.4 million in aggregate gross proceeds through an underwritten public offering of common stock with Oppenheimer & Co. Inc. acting as the sole book-running manager and National Securities Corporation acting as a co-manager in connection with the offering. Our cash position was further strengthened in 2018 with a private placement (PIPE) of common stock and warrants to an existing shareholder for aggregate gross proceeds of $9 million (excluding any proceeds from the exercise of warrants). During 2018, existing investors also exercised warrants to purchase common stock that resulted in approximately $717,000 in aggregate net proceeds.

We have also continued to attract non-dilutive funding, especially from the Walloon region, Belgium, which has provided over $3.7 million in funds to-date.

Our research and development program is remarkably cost-effective, especially given the size of the trials and the nature of our collaborations with leading institutions. Consequently, we continue to manage cash carefully and had a steady cash burn rate of approximately $3.9 million per quarter during 2018.

In the first quarter of 2019, over $6.7 million in aggregate gross proceeds has been received from the exercise of warrants to purchase common stock, which demonstrated continued support from our dedicated investors and further strengthens our cash position.

David
Chief Financial Officer

It is great to be working with a skilled and passionate team focused on saving lives and reducing the cost of cancer to healthcare systems around the world.

Rod
Corporate Secretary

Our worldwide portfolio of granted patents that protects various aspects of Volition’s Nu.Q technology is growing.

We have 20 patent families related to our diagnostic tests, with 7 patents granted in the United States and 7 patents granted in the European Union and a further 25 patents granted worldwide. Additionally, we have 106 patent applications pending worldwide. This portfolio also covers veterinary medicine applications.

We intend to continue our development of the Nucleosomics technologies and to apply for patents identified through such efforts. Our strategy is to protect our technologies and leverage the strength of our intellectual property portfolio to gain market exclusivity in Europe, the United States and in other strategic countries. The patents on the technologies underlying our products should provide broad coverage for each product, including protection through at least 2031 for products developed using the Nu.Q technologies.

We have signed multiple contracts throughout 2018 with our growing team of collaborators and look forward to adding even more to the list in 2019.

The whole team is committed and passionate about the work we do.
Using our Nu.Q technology, we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing.

The principle behind what we are doing relies on bringing together two main lines of research and is, in concept, very simple:

The chromosomes of cancer cells differ from those of healthy cells – both in terms of DNA sequence (due to genetic cancer mutations) and in protein structure – due to epigenetic changes.

There are chromosome fragments from dead cancer cells circulating in the blood as nucleosomes. Each such circulating nucleosome contains a small (approximately 140 base pairs) fragment of tumor DNA.

Volition’s Nucleosomics technology exploits the different compositions of circulating nucleosome structures present in the blood of cancer patients to detect and identify cancer diseases.

We are developing a novel suite of blood assays of epigenetically altered circulating nucleosomes as biomarkers in cancer and other diseases. Nu.Q products aim to be simple, low-cost, enzyme-linked immunosorbent assay (“ELISA”) platform tests and can incorporate other biomarkers such as anti-inflammatory markers and/or low-cost ELISA tests in our panels (e.g. CEA, PSA, CA125) for higher accuracy.

Many companies and medical schools are developing circulating tumor DNA or ctDNA tests based on sequencing the DNA attached to these nucleosomes. Volition’s diagnostic target in the blood is the same tumor chromosome fragment, but our approach is to test for chromosome protein and nucleic acid changes in intact chromosome fragments by ELISA, rather than chemically extracting, amplifying, and sequencing the ctDNA and discarding the rest of the nucleosome. ELISA is possible because the targets of our tests occur globally across all nucleosomes within a tumor cell, whereas individual ctDNA changes must be identified within the three billion base-pair genomes. This means that the targets of our tests are exponentially more prevalent in circulating blood, and detectable using simple laboratory methods.

How is Nu.Q different from ctDNA?

- When a cancer cell dies the nuclear components are metabolized into 20 million individual DNA-Nu complexes and released into circulation. A cancer mutation will occur in one of the DNA-Nu complexes.
- ctDNA sequencing methods (in development) must target that one-in-a-million DNA-Nu complex.
- Nu.Q targets ALL 20 million circulating DNA-Nu complexes because nucleosome modifications occur globally.
- Nu.Q is a simple, low-cost ELISA and can incorporate other ELISA tests in Volition’s panels.

There are multiple phases to the Product Development process, and we are delighted in 2018 to have made the **significant step forward** in developing some of our Nu.Q assays to **product grade status** (by which we mean analytically validated and of clinical grade, so that they can be reproducible anywhere, in any laboratory), so that clinical trials may commence.
How it works

The genome is 3 billion base pairs. If uncoiled it would measure 5 feet long. Every 140 base pairs of DNA are wrapped around a nucleosome to form a DNA-Nu complex.

Nucleosomes consist of DNA and histone proteins. Histones and DNA are subjected to a variety of epigenetic modifications.

Cancer leads to cell death which results in fragmentation and release of nucleosomes into the blood.

Our Nucleosomics technology exploits the different compositions of circulating nucleosome structures present in the serum of cancer patients to detect and identify cancer diseases.

The DNA in every cell is wound around protein complexes in a “beads on a string” structure.
The global cancer market: 2018

Globocan Project, Ferlay et al.

There were 18.1 million cancer diagnoses worldwide in 2018 with a resulting mortality burden of almost 10 million people. Given the growing and more importantly aging population, cancer’s burden is expected to worsen.

By 2040 it is predicted that there will be 29.5 million new cases of cancer diagnosed each year and over 16 million cancer-related deaths.
We work hard every day to help change people’s lives throughout the world.

**Product Strategy.**

We anticipate that we will develop multiple Nu.Q products across the whole range of cancers falling into the following categories:

1. **Frontline General Population Screening Tests**
   - For asymptomatic subjects for the most prevalent cancers.
2. **High Risk Screening ‘Triage’ Tests**
   - To work in conjunction with existing tests to improve sensitivity and/or specificity.
3. **Frontline Diagnostic Tests**
   - To aid the diagnosis of disease in symptomatic patients.
4. **Disease Monitoring Tests**
   - To help monitor high risk groups and/or identify the recurrence of a disease.
5. **Treatment Selection Tests**
   - A personalized medicine approach to help identify the most appropriate treatment for the individual.

**Cancers currently being researched with product grade assays include:**

<table>
<thead>
<tr>
<th>Cancers</th>
<th>Proof of Concept</th>
<th>Training</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lung</td>
<td></td>
<td>2019</td>
<td>2020</td>
</tr>
<tr>
<td>Colorectal</td>
<td></td>
<td>2019</td>
<td>2020</td>
</tr>
<tr>
<td>Prostate</td>
<td></td>
<td>2020</td>
<td>2021</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>2019</td>
<td>2020</td>
<td>tbc</td>
</tr>
<tr>
<td>Ovarian</td>
<td>2019</td>
<td>2020</td>
<td>tbc</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>2019</td>
<td>tbc</td>
<td>tbc</td>
</tr>
<tr>
<td>Gastric</td>
<td>2019</td>
<td>tbc</td>
<td>tbc</td>
</tr>
<tr>
<td>27 Most Prevalent Cancers</td>
<td>2019</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Product grade assays - Proof of concept data

In a small multi-cancer cohort (N=50) a single Nu.Q assay detected colorectal, lung, and prostate cancer.

In the same cohort a 2-assay panel detected all stages of colorectal cancer including stage I and had an AUC of 85%.

In a small colorectal cancer cohort (N=123) a single Nu.Q assay detected colorectal cancer with an AUC of 72%.

In a small lung cancer cohort (N=76) the same single Nu.Q assay detected lung cancer including stage I lung cancer. The AUC for this single Nu.Q assay was 85%.

This performance was further improved when used in combination within a 2-assay panel.

In a second lung cancer cohort (N=152) the same Nu.Q assay detected lung cancer. The AUC for this single Nu.Q assay was 79%.

Again, this performance was further improved when used in a two-assay panel.
A focus on Asia

We have expanded our relationship with the National Taiwan University.

In addition to the large colorectal cancer studies, we have recently announced a prospective lung cancer study involving 1,200 subjects. Lung cancer remains the deadliest of all the cancers and we believe that there is a high unmet clinical need for a non-invasive early stage lung cancer detection and/or for a test which can improve the specificity of the low-dose CT scan currently used in many markets. We are hopeful that our recent proof of concept results in lung cancer will be repeated in this much larger cohort.

Our large-scale colorectal cancer studies are well underway with National Taiwan University. The first trial, a multi-center study will include 5,000 asymptomatic screening subjects to evaluate the performance of our Nu.Q Frontline Asymptomatic Colorectal Cancer Screening Test. The second study includes 2,000 symptomatic patients and will be used to evaluate the performance of our Nu.Q colorectal cancer symptomatic test. Professor Han-Mo Chiu and his team are collecting well ahead of schedule and we look forward to reporting some preliminary results in 2019.

We have made significant progress with our entrance into China with a collaboration with Shanghai Fosun Long March (an IVD company wholly owned by Fosun Pharmaceutical Group Co Ltd, a leading healthcare company in China).

With Fosun Long March, we plan to conduct three clinical studies on colorectal, lung and ovarian cancers in China. In addition, we are jointly exploring the development of Nu.Q assays utilizing their LUMIART-II Automated Chemiluminescence Immunoassay System.

We are excited that our work in China will be underway in 2019 and look forward to a successful collaboration with Fosun Long March.

The programs we have launched with collaborators worldwide speak well of the belief they have in our technology and our team. We are getting closer in realising our vision to develop an effective platform to detect cancers early.

Jasmine
Chief Executive Officer,
Singapore Volition
In the fourth quarter of 2018, we were delighted to present some very encouraging preliminary results from a proof of concept study using our Nu.Q diagnostics platform in veterinary medicine.

The proof of concept study demonstrated that nucleosomes can be detected in dogs and therefore, have the potential to differentiate cancer from other conditions in canines. Following the completion of several small-scale studies in dogs, our subsidiary Volition America Inc. is now conducting a study in cancer and other diseases in collaboration with a Texas A&M University’s College of Veterinary Medicine, a leading U.S. veterinary institution. We hope that this study will advance our plans to partner with academic and industry leaders to expedite regulatory approval and product commercialization.

The U.S. is currently the largest veterinary market in the world and has a clearly defined regulatory pathway via the USDA, requiring fewer and smaller clinical studies than the FDA process for human diagnostics. This generally allows a much faster route to revenue for veterinary products as compared to human products.

From a commercial point of view, we are extremely excited about the opportunity to offer Nu.Q Vet tests to animal owners and veterinarians. There are currently no accurate, simple, affordable cancer screening or diagnostic tests available in veterinary medicine and yet 25% of dogs will develop cancer at some stage of their life.

Volition’s extensive intellectual property portfolio includes coverage of veterinary applications. We believe that licensing this technology could potentially provide significant revenue for Volition, in addition to providing further technical validation of our platform.

It’s exciting that not only could our Nu.Q technology help save lives and improve the quality of life for man-kind, but we are hopeful our technology will be effective in helping diagnose a range of diseases in animals.

Cancer doesn’t discriminate – it causes fear, pain and suffering for all those it touches. Early diagnosis is a critical component of curing cancer.
It is tremendously rewarding working on such a cutting-edge technology - one that has the potential to not only help diagnose cancer, but also potentially many other conditions.

We were delighted to sign a global license, manufacturing, sales and distribution agreement with Active Motif for a range of Research Use Only kits. Based on our proprietary Nucleosomics technology, the kits are expected to:

- Allow researchers to explore patterns of epigenetic modifications in circulating nucleosomes across a broad range of clinical applications including cancers, inflammatory and infectious diseases; and
- Represent the first revenue from the Nu.Q platform and potentially provide an additional licensing revenue stream beyond the commercialization of our blood-based cancer tests utilizing the same platform of assays.

The first kit was launched in the second half of 2018 and we look forward to expanding the range of available kits throughout 2019 and beyond.

In addition to the RUO Kit development we have also done a lot of broader work on our platform including adapting our assays for magnetic beads and chemiluminescence, both very important breakthroughs which could make our platform much more adaptable and robust.
Our research and development team has grown significantly since we moved into our larger, purpose-built laboratory in Belgium, in 2017. This has enabled expansion of our research and development programs from our Nu.Q diagnostic tests to now include not only Nu.Q Vet but also Nu.Q Capture.

The Nu.Q Capture project leverages the work we have been doing to investigate the use of Nucleosomics to purify or enrich tumor associated nucleosomes. Thus far with Nu.Q Capture we have been able to deplete/enrich nucleosomes by 70-90% using magnetics beads in serum and plasma.

The next step is to determine the level of discrimination of tumor associated nucleosomes using mass spectrometry and/or sequencing. This potential breakthrough product aims to enrich tumor associated DNA which in turn will help address the main technology barrier to DNA cancer diagnostics. Nu.Q Capture is platform agnostic with the ultimate aim of providing complete nucleosome analysis and origin of cancer.

Depletion/Enrichment

- Nu.Q™ Mass Spec
- Nu.Q™ Seq
- Nu.Q™ Immunoassay
- Complete Nucleosome Analysis

Commercial concept
Complete Nucleosome analysis.
## The Volition Biobank

<table>
<thead>
<tr>
<th>Institution</th>
<th>Condition</th>
<th>Sample Collection</th>
<th>Cohort</th>
<th>Timing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Detection Research Network of the U.S. National Cancer Institute</td>
<td>Colorectal</td>
<td>9,000 Prospective, 4,600 Retrospective</td>
<td>13,500 + Screening Population</td>
<td>Ongoing to 2020</td>
</tr>
<tr>
<td>National Taiwan University</td>
<td>Colorectal</td>
<td>Prospective</td>
<td>5,000 Asymptomatic Population</td>
<td>Ongoing to 2021</td>
</tr>
<tr>
<td>National Taiwan University</td>
<td>Colorectal</td>
<td>Prospective</td>
<td>2,000 Symptomatic Patients</td>
<td>Ongoing to 2021</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal</td>
<td>Prospective</td>
<td>14,000 Screening Population</td>
<td>Collection completed and analysis ongoing</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal</td>
<td>Prospective</td>
<td>30,000 Screening Population</td>
<td>Collection completed and analysis ongoing</td>
</tr>
<tr>
<td>Hvidovre Hospital, University of Copenhagen</td>
<td>Colorectal</td>
<td>Retrospective</td>
<td>4,800 Symptomatic Patients</td>
<td>Collection completed and analysis ongoing</td>
</tr>
<tr>
<td>National Taiwan University</td>
<td>Lung</td>
<td>Prospective</td>
<td>1,200 Subjects</td>
<td>Expected to start mid-2019 to 2021</td>
</tr>
<tr>
<td>German Cancer Research Center (DKFZ)</td>
<td>Pancreatic</td>
<td>Retrospective</td>
<td>750 Subjects</td>
<td>Collection completed and analysis ongoing</td>
</tr>
<tr>
<td>University of Bonn</td>
<td>27 Most Prevalent Cancers</td>
<td>Prospective</td>
<td>4,500 Subjects</td>
<td>Collection completed and analysis ongoing</td>
</tr>
</tbody>
</table>

## Proof of Concept

<table>
<thead>
<tr>
<th>Condition</th>
<th>Sample Cohort</th>
<th>Expected Data Release</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorectal</td>
<td>N = 225</td>
<td>Q2 2019</td>
</tr>
<tr>
<td>Colorectal</td>
<td>N = 552</td>
<td>H1 2019</td>
</tr>
<tr>
<td>Colorectal</td>
<td>N = 352</td>
<td>H2 2019</td>
</tr>
<tr>
<td>Lung</td>
<td>N = 76</td>
<td>Q1 2019</td>
</tr>
<tr>
<td>Lung</td>
<td>N = 152</td>
<td>H1 2019</td>
</tr>
<tr>
<td>Prostate</td>
<td>N = 120</td>
<td>H1 2019</td>
</tr>
<tr>
<td>Prostate</td>
<td>N = 100</td>
<td>H2 2019</td>
</tr>
<tr>
<td>Pancreatic</td>
<td>N = 100</td>
<td>H2 2019</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>N = 200</td>
<td>H2 2019</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>N = 10 (x 5 collections)</td>
<td>H2 2019</td>
</tr>
<tr>
<td>Endometriosis</td>
<td>N = 300</td>
<td>H2 2019</td>
</tr>
</tbody>
</table>
We have a very active investor relations program, attending numerous investor-focused conferences annually, and conducting investor presentations in major financial centers across the United States and Europe on a regular basis. Our goal is to raise the awareness of Volition and its mission in order to broaden the investor base and ultimately to maximize shareholder value.

Volition is very fortunate to have attracted numerous long-term shareholders to our Company who share the same vision of revolutionizing cancer diagnostics, helping people find cancer earlier, and improving outcomes for millions of people worldwide.

For any further information please contact investorrelations@volitionrx.com

It is such a pleasure to be involved with a company that has the potential to do so much good for humanity while providing potential upside to shareholders.
Investor information.
Annual Meeting: Friday June 14, 2019